Merck

MRK · Xetra · EUR

€136.90+1.82%+€2.45

Close · October 2, 2026

At a glance

Revenue growth: +1.31%; 2025 vs 2024
Net income growth: +6.64%; 2025 vs 2024
Net margin: 28.1%; 2024: 26.7%

Financial data

Amounts in millions of EUR; per-share values in EUR; shares in millions.

Income statement · Quarterly
Item	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023
Total revenue	5,434	5,134	5,249	5,318	5,255	5,280	5,418	5,266	5,352	5,120	5,225	5,173
Cost of revenue	2,268	2,069	2,205	2,105	2,228	2,136	2,278	2,122	2,119	2,111	2,284	2,162
Gross profit	3,166	3,065	3,044	3,213	3,027	3,145	3,140	3,144	3,233	3,009	2,941	3,011
Selling, general and administrative	1,565	1,517	1,543	1,460	1,476	1,481	1,483	1,410	1,482	1,419	1,306	1,416
Research and development	684	658	634	660	539	551	516	524	647	581	659	581
Operating income	753	935	926	1,221	891	992	1,390	1,097	793	931	849	984
EBIT	753	935	926	1,221	891	992	1,390	1,097	793	931	849	984
EBITDA	1,250	1,420	1,308	1,679	1,325	1,446	1,503	1,546	1,240	1,385	1,210	1,419
Interest expense	137	80.6	43.0	126	79.0	61.3	328	89.0	72.0	74.0	4.0	84.0
Pre-tax income	640	869	401	1,123	829	956	810	1,043	785	899	641	938
Income tax	146	200	77.0	225	174	218	140	231	180	200	53.0	197
Net income	490	659	319	902	652	735	667	809	607	694	586	739
Net income to common shareholders	490	659	319	902	652	735	667	809	607	694	586	739
Basic EPS	1.13	1.52	0.73	2.07	1.50	1.69	1.53	1.86	1.40	1.60	1.35	1.70
Diluted EPS	1.13	1.52	0.73	2.07	1.50	1.69	1.53	1.86	1.40	1.60	1.34	1.70
Average shares (basic)	434	434	435	436	435	435	435	435	434	434	435	435
Average shares (diluted)	434	434	435	436	435	435	435	435	434	434	435	435
Dividend per share	0.85	0.85	2.20	0.81	0.81	0.81	2.20	0.77	0.77	0.77	2.20	—